Experience
Fochon Pharmaceuticals, Ltd.
Drafted and negotiated a complex license agreement for Fochon Pharmaceuticals, Ltd. relating to BCL-2 inhibitors with up to $400 million in potential development and commercial milestones.
InnoPharma Licensing, Inc.; Lupin Ltd.; and Metrics, Inc. v. Senju Pharmaceuticals Co.
Bausch Health Companies
Mylan Pharmaceuticals Inc. v. Senju Pharmaceutical Co., Ltd.
Senju Pharmaceutical Co., Ltd.; Bausch & Lomb Incorporated
Housey Pharmaceuticals, Inc. v. Otsuka Pharmaceutical Co. Ltd.
Otsuka Pharmaceutical Co. Ltd.
Otsuka Pharmaceutical Co., Ltd. v. Teva Pharmaceuticals USA, Inc.
Otsuka Pharmaceutical Co.
Hartig Drug Co. Inc. v. Senju Pharmaceutical Co. Ltd.
Senju Pharmaceuticals Co. Ltd.
Senju Pharmaceutical Co., Ltd. v. Apotex Inc.
Senju Pharmaceutical Co., Ltd.; Bausch + Lomb Inc.
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.